Compare SCL & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCL | OGN |
|---|---|---|
| Founded | 1932 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 1994 | 2020 |
| Metric | SCL | OGN |
|---|---|---|
| Price | $64.50 | $13.74 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 5 |
| Target Price | ★ $75.00 | $11.40 |
| AVG Volume (30 Days) | 97.4K | ★ 2.5M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.23% | 0.60% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.95 |
| Revenue | $1,803,737,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $6.60 | $0.45 |
| Revenue Next Year | $5.27 | $1.67 |
| P/E Ratio | ★ N/A | $14.44 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $41.82 | $5.69 |
| 52 Week High | $68.00 | $13.79 |
| Indicator | SCL | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 58.59 | 59.92 |
| Support Level | $60.29 | $13.46 |
| Resistance Level | $66.33 | $13.79 |
| Average True Range (ATR) | 1.45 | 0.04 |
| MACD | 0.24 | -0.00 |
| Stochastic Oscillator | 82.46 | 70.00 |
Stepan Co manufactures and sells a variety of chemicals and chemical-based products. The company organizes itself into three segments based on product type. The surfactants segment, which generates the majority of revenue, sells cleaning agents used in detergents, shampoos, body wash, fabric softeners, toothpastes, and other personal-care products. The polymers segment sells polyurethane used to manufacture rigid foam for thermal insulation, as well as phthalic anhydride used to make plastic components for the construction, automotive, and boating industries. The specialty products segment sells chemicals used in food and flavoring. The majority of Stepan's revenue comes from the United States, followed by France, Poland, the United Kingdom, Brazil, Mexico, and other countries.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.